Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (symbol: BLCO) is a prominent player in the vision care industry based in Madrid, Spain. Originally part of Bausch Health, Bausch + Lomb became a public company in 2022. It operates in three primary segments: vision care, surgical, and ophthalmic pharmaceuticals.
Vision Care Segment: This segment covers contact lenses and ocular health products. Bausch + Lomb holds a 10% market share in contact lenses, and its portfolio includes popular brands such as Biotrue and Lumify.
Surgical Segment: This includes intraocular lenses and equipment for cataract and vitreoretinal surgeries. The company also provides a range of surgical instruments, making it a comprehensive provider in the surgical eye care market.
Ophthalmic Pharmaceuticals: Bausch + Lomb offers over 100 products, including Xipere, Vyzulta, and Lotemax, which are designed to treat various eye conditions. This extensive lineup makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market.
With a strong commitment to innovation and quality, Bausch + Lomb continuously works on new projects and partnerships to enhance its product offerings. The company’s diverse portfolio and strategic initiatives ensure its significant role in the vision care industry.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announces participation at the World Cornea Congress VIII on September 28-29, 2022, in Chicago. Key presentations include one podium and two poster presentations showcasing pivotal findings from Phase 3 trials of the investigational treatment NOV03 (perfluorohexyloctane) and data from its ARMOR surveillance study, which monitors antibiotic resistance among ocular pathogens. The FDA has recently accepted Bausch + Lomb's New Drug Application for NOV03, indicating progress in their clinical development program.
Bausch + Lomb will present seven scientific podium and poster presentations at the American Academy of Ophthalmology (AAO) annual meeting in Chicago, scheduled from September 30 to October 3, 2022. Key presentations will focus on investigational treatment NOV03 for dry eye disease, a biosimilar candidate to Lucentis, and other products. The company will sponsor two educational events discussing dry eye disease, a condition affecting approximately 18 million Americans. This marks Bausch + Lomb's first participation as a publicly traded company.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced a webinar to discuss findings from the National Eye Institute's 10-Year Follow-on Study of the Age-Related Eye Disease Study 2 (AREDS2). The webinar, titled "More InSight: A Closer Look at the New AREDS2 Data and What It Means For Patients," will take place on October 18, 2022. The session aims to help eye care professionals understand how to apply the study results regarding a specific nutrient formula's impact on Age-related Macular Degeneration (AMD) patients. Key insights will be provided by leading experts in the field.
Bausch + Lomb released its inaugural Visionary Report on September 13, 2022, highlighting the lack of awareness regarding Age-related Macular Degeneration (AMD) among Americans over 50. Despite 81% of respondents prioritizing eyesight, only 37% recognize AMD as a significant threat. Approximately 16 million Americans suffer from AMD, with this number expected to rise. The report indicates a critical gap in understanding AMD, as 61% are unaware that a dilated eye exam is required for diagnosis. Bausch + Lomb aims to enhance awareness and education about AMD through this report.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) and Novaliq GmbH announced the FDA's acceptance of their New Drug Application (NDA) for NOV03, an investigational eye drop for treating dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). The PDUFA action date is set for June 28, 2023. This could mark Bausch + Lomb's first FDA approval for a prescription medicine since going public. Current treatments for DED related to MGD are limited, making NOV03 a promising therapy aimed at reducing tear evaporation.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has entered an exclusive distribution agreement with Alfa Instruments to market its line of surgical intraocular dyes, named Vitreocare, globally (excluding Italy). This partnership aims to enhance Bausch + Lomb's surgical portfolio by incorporating clinically proven dyes that improve visibility during various eye surgeries. The distribution is expected to begin in the EU, excluding Italy, in early 2023. The dyes have received CE marking in the EU, UK, and Switzerland, demonstrating their safety and effectiveness for eye care professionals.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced participation in two upcoming investor conferences. The company's CEO, Joseph C. Papa, CFO Sam Eldessouky, and SVP Arthur J. Shannon will represent Bausch + Lomb at the Wells Fargo 2022 Healthcare Conference on Sept. 7, 2022, at 1:55 p.m. ET in Boston, and the 20th Annual Morgan Stanley Global Healthcare Conference on Sept. 13, 2022, at 10:00 a.m. ET in New York. A live webcast will be available on the company's Investor Relations page.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) reported second-quarter 2022 revenues of $941 million, growing 1% year-over-year. Organic revenues increased 6%, driven by strong performance in the Vision Care segment, which saw a 6% rise to $589 million. Net income was $5 million, down from $44 million in Q2 2021. Cash flow from operations decreased by $94 million to $156 million. Bausch + Lomb reaffirmed its full-year revenue guidance between $3.75 billion and $3.80 billion, forecasting 4-5% organic growth.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced the U.S. launch of the #LUMIFYEyeDance Challenge on TikTok, starting July 25, 2022, and ending August 31, 2022. Participants can win a $10,500 prize package, including travel to New York and a makeover by celebrity makeup artist Vincent Oquendo. The initiative aims to build on the existing popularity of LUMIFY® products, which have garnered nearly 14 million views on TikTok. Additionally, a national product sampling tour will take place in major U.S. cities throughout August, featuring engaging experiences and opportunities for consumers.
Bausch + Lomb has made an equity investment in Sanoculis and signed an exclusive European distribution agreement for the MIMS® glaucoma treatment, enhancing their commitment to addressing unmet needs in glaucoma care. MIMS® is a minimally invasive surgical procedure that lowers intraocular pressure without stent implantation, with a CE marking confirming its safety. This strategic move aims to leverage Bausch + Lomb's distribution network in Europe, enabling better access to innovative glaucoma treatments for specialists and patients. The increasing prevalence of glaucoma presents a growing market opportunity for both companies.
FAQ
What is the current stock price of Bausch + Lomb Corporation (BLCO)?
What is the market cap of Bausch + Lomb Corporation (BLCO)?
What does Bausch + Lomb Corporation do?
When did Bausch + Lomb become a public company?
What are the primary segments Bausch + Lomb operates in?
What are some key products in Bausch + Lomb's vision care segment?
What does Bausch + Lomb offer in its surgical segment?
What products are included in Bausch + Lomb's ophthalmic pharmaceuticals segment?
Where is Bausch + Lomb Corporation headquartered?
What market share does Bausch + Lomb hold in the contact lenses market?
What makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market?
What is Bausch + Lomb's commitment towards its products and services?
